These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 32967856)

  • 1. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
    Filion KB; Lix LM; Yu OH; Dell'Aniello S; Douros A; Shah BR; St-Jean A; Fisher A; Tremblay E; Bugden SC; Alessi-Severini S; Ronksley PE; Hu N; Dormuth CR; Ernst P; Suissa S;
    BMJ; 2020 Sep; 370():m3342. PubMed ID: 32967856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
    Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
    Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
    Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
    BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
    Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Persson F; Nyström T; Jørgensen ME; Carstensen B; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Eriksson JW; Norhammar A; Bodegard J; Birkeland KI
    Diabetes Obes Metab; 2018 Feb; 20(2):344-351. PubMed ID: 28771923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
    BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
    Wu MZ; Chandramouli C; Wong PF; Chan YH; Li HL; Yu SY; Tse YK; Ren QW; Yu SY; Tse HF; Lam CSP; Yiu KH
    Diabetes Metab; 2022 Nov; 48(6):101367. PubMed ID: 35753654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
    Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
    Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
    Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
    Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
    Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
    J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
    Shao SC; Chang KC; Hung MJ; Yang NI; Chan YY; Chen HY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2019 Sep; 18(1):120. PubMed ID: 31551068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies.
    Mascolo A; Scavone C; Scisciola L; Chiodini P; Capuano A; Paolisso G
    Pharmacol Res; 2021 Oct; 172():105836. PubMed ID: 34418562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.